Floatz logo

Tenofovir Alafenamide

Chronic Hepatitis b

Ningbo No.2 HospitalSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Chronic Hepatitis b cohort.

Asset / SponsorPhaseRating
Lamivudine
Yonsei University
Phase 4BBB
Entecavir
Beijing Continent Pharmaceutical Co, Ltd.
Phase 4BBB
TENOFOVIR DISOPROXIL FUMARATE
Ningbo No.2 Hospital
Phase 4BBB
Telbivudine
The Fifth People's Hospital of Suzhou
Phase 4BBB
Adefovir Dipivoxil
Asian-Pacific Alliance of Liver Disease, Beijing
Phase 4BB

View all 29 →

Same molecule, other indications

Tenofovir Alafenamide is also rated in:

HIV infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
chronic hepatitis B virus infectionDormant
BB
Indicative ·
69 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →